11/17/20 8:29 AMNasdaq : BMRNBioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial IntelligenceBioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical collaboration that will use Deep Genomics' artificial intelligence drug discovery platform (The AIRHEA-AIpositive
11/12/20 8:30 AMNasdaq : BMRNBioMarin to Participate in Three Upcoming Virtual Investor ConferencesBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in three upcoming virtual conferences. An audio webcast of the presentations will be available live. You can access the webcast at:RHEA-AIneutral
11/09/20 8:31 AMNasdaq : BMRNBioMarin Expands Vosoritide Clinical ProgramBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the Company is expanding its clinical program for vosoritide, an investigational analog of C-type Natriuretic Peptide (CNP), with two new Phase 2 studies. The first study is sponsoredRHEA-AIneutral
11/05/20 4:05 PMNasdaq : BMRNBioMarin Announces Third Quarter 2020 Total Revenues of $477 MillionFinancial Highlights (in millions of U.S. dollars, except per share data, unaudited)Three Months Ended September 30,Nine Months Ended September 30,20202019% Change20202019% ChangeTotalRHEA-AIneutral
11/04/20 8:30 AMNasdaq : BMRNBioMarin to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on November 10 at 12:30pm ETBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaime, Chairman and Chief Executive Officer, and Brian Mueller, Executive Vice President, Chief Financial Officer, will participate in the Credit Suisse 29th AnnualRHEA-AIneutral
11/02/20 8:55 PMNasdaq : BMRNFood and Drug Administration Accepts BioMarin's New Drug Application for Vosoritide to Treat Children with AchondroplasiaBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for vosoritide, an investigational, once daily injection analog of C-type Natriuretic PeptideRHEA-AIvery positive
10/22/20 8:30 AMNasdaq : BMRNBioMarin to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5 at 4:30pm ETBioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaime, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, November 5, at 4:30 p.m. ET to discuss third quarter 2020RHEA-AIneutral
10/07/20 8:31 AMNasdaq : BMRNBioMarin, Pioneer in Rare Disease Treatments for Phenylketonuria (PKU), Receives FDA Approval of Label Expansion to Allow Maximum Dose of 60 mg for Palynziq(R) (pegvaliase-pqpz) Injection for Treatment of Adults with PKUBioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) to increase the maximum allowable dose of 60 mg with Palynziq(R)RHEA-AIneutral
10/05/20 8:31 AMNasdaq : BMRNScientific Luminary and MacArthur Fellowship Winner, Kevin Eggan, Ph.D., Joins BioMarin as Head of Research and Early DevelopmentBioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the Company hired scientific luminary and MacArthur Fellowship winner, Kevin Eggan, Ph.D., as Group Vice President, Head of Research and Early Development, effective today. Dr. Eggan bringsRHEA-AIvery positive
10/02/20 8:31 AMNasdaq : BMRNBioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a pioneer in developing treatments for phenylketonuria (PKU) and gene therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BMN 307, anRHEA-AIvery positive
